PHR Quote, Financials, Valuation and Earnings

Cryo-Cell International has a net margin of -3.38% compared to Phreesia's net margin of 4.49%. Phreesia's return on equity of -16.36% beat Cryo-Cell International's return on equity of --.

Phreesia has a consensus price target of $32.14, signalling upside risk potential of 23.96%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 75.26%. Given that Cryo-Cell International has higher upside potential than Phreesia, analysts believe Cryo-Cell International is more attractive than Phreesia.

Phreesia has a beta of 0.719, which suggesting that the stock is 28.109% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.131%.

Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 13.4% to investors and pays a quarterly dividend of $0.15 per share. Phreesia pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

Phreesia quarterly revenues are $115.9M, which are larger than Cryo-Cell International quarterly revenues of $7.9M. Phreesia's net income of -$3.9M is lower than Cryo-Cell International's net income of $355.8K. Notably, Phreesia's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.47x versus 1.25x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Evolent Health has a net margin of -3.38% compared to Phreesia's net margin of -13.36%. Phreesia's return on equity of -16.36% beat Evolent Health's return on equity of -10.73%.

Phreesia has a consensus price target of $32.14, signalling upside risk potential of 23.96%. On the other hand Evolent Health has an analysts' consensus of $15.23 which suggests that it could grow by 35.14%. Given that Evolent Health has higher upside potential than Phreesia, analysts believe Evolent Health is more attractive than Phreesia.

Phreesia has a beta of 0.719, which suggesting that the stock is 28.109% less volatile than S&P 500. In comparison Evolent Health has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.544%.

Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evolent Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phreesia pays -- of its earnings as a dividend. Evolent Health pays out -32.59% of its earnings as a dividend.

Phreesia quarterly revenues are $115.9M, which are smaller than Evolent Health quarterly revenues of $483.6M. Phreesia's net income of -$3.9M is higher than Evolent Health's net income of -$64.6M. Notably, Phreesia's price-to-earnings ratio is -- while Evolent Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.47x versus 0.54x for Evolent Health. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of -3.38% compared to Phreesia's net margin of -2.6%. Phreesia's return on equity of -16.36% beat Omnicell's return on equity of 1.73%.

Phreesia has a consensus price target of $32.14, signalling upside risk potential of 23.96%. On the other hand Omnicell has an analysts' consensus of $43.33 which suggests that it could grow by 54.93%. Given that Omnicell has higher upside potential than Phreesia, analysts believe Omnicell is more attractive than Phreesia.

Phreesia has a beta of 0.719, which suggesting that the stock is 28.109% less volatile than S&P 500. In comparison Omnicell has a beta of 0.761, suggesting its less volatile than the S&P 500 by 23.879%.

Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phreesia pays -- of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

Phreesia quarterly revenues are $115.9M, which are smaller than Omnicell quarterly revenues of $269.7M. Phreesia's net income of -$3.9M is higher than Omnicell's net income of -$7M. Notably, Phreesia's price-to-earnings ratio is -- while Omnicell's PE ratio is 60.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.47x versus 1.15x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

Premier has a net margin of -3.38% compared to Phreesia's net margin of 10.36%. Phreesia's return on equity of -16.36% beat Premier's return on equity of 3.44%.

Phreesia has a consensus price target of $32.14, signalling upside risk potential of 23.96%. On the other hand Premier has an analysts' consensus of $22.00 which suggests that it could grow by 4.41%. Given that Phreesia has higher upside potential than Premier, analysts believe Phreesia is more attractive than Premier.

Phreesia has a beta of 0.719, which suggesting that the stock is 28.109% less volatile than S&P 500. In comparison Premier has a beta of 0.559, suggesting its less volatile than the S&P 500 by 44.103%.

Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Premier offers a yield of 3.99% to investors and pays a quarterly dividend of $0.21 per share. Phreesia pays -- of its earnings as a dividend. Premier pays out 79.64% of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phreesia quarterly revenues are $115.9M, which are smaller than Premier quarterly revenues of $261.4M. Phreesia's net income of -$3.9M is lower than Premier's net income of $27.1M. Notably, Phreesia's price-to-earnings ratio is -- while Premier's PE ratio is 39.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.47x versus 1.63x for Premier. Usually stocks with elevated PS ratios are considered overvalued.